- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | FluoGuide A/S: Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG | 34 | GlobeNewswire (Europe) | Copenhagen, Denmark, 10 April 2026 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company maximizing surgical outcomes in oncology by lighting up cancer.
The interim data from... ► Artikel lesen | |
| 25.03. | Minutes from Annual General Meeting in FluoGuide A/S | 263 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 25, 2026 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company") held its annual general meeting on 25 March 2026.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 18.03. | FluoGuide A/S: FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma | 225 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces... ► Artikel lesen | |
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 10.03. | Notice of Annual General Meeting in FluoGuide A/S | 386 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / March 10, 2026 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025 | 319 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Interim Report For Q4 2025 | 283 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report... ► Artikel lesen | |
| 20.02. | FluoGuide A/S: FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track | 628 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer... ► Artikel lesen | |
| 19.02. | Invitation to FluoGuide A/S Live Webcast on 25 February 2026 | 227 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / February 19, 2026 / FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 21.01. | FluoGuide A/S: FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial | 266 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.11.25 | FluoGuide A/S Publishes Interim Report Q3 2025 | 349 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen | |
| 25.11.25 | FluoGuide A/S: FluoGuide Signs Collaboration Agreement with ZEISS | 395 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces... ► Artikel lesen | |
| 24.11.25 | Minutes from Extraordinary General Meeting in FluoGuide A/S | 315 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide... ► Artikel lesen | |
| 24.11.25 | Invitation to FluoGuide A/S Webcast on 27 November 2025 | 312 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.The following event will take place... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy | 382 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Convenes an Extraordinary General Meeting | 300 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") hereby invites shareholders to participate in an extraordinary general meeting to be... ► Artikel lesen | |
| 03.11.25 | FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees | 349 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, members... ► Artikel lesen | |
| 03.11.25 | FluoGuide A/S Completes Directed Share Issue of SEK 104 Million | 366 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 03.11.25 | FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million | 637 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER... ► Artikel lesen | |
| 28.10.25 | FluoGuide A/S: FluoGuide in Advanced Negotiations on Collaboration Agreement with a World Leading Medical Technology Company | 227 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / October 28, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company specializing in precision cancer surgery, announces to be in advanced... ► Artikel lesen | |
| 16.09.25 | FluoGuide A/S: FluoGuide Receives Positive FDA Feedback on FG001 in High-Grade Glioma | 312 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / September 16, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") received positive feedback and alignment with the FDA at a pre-IND consultation on its U.S. clinical... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALIGNMENT HEALTHCARE | 21,380 | 0,00 % | Alignment Healthcare (ALHC) Soars 16% on Medicare Reimbursement Hike | ||
| FRESENIUS MEDICAL CARE | 40,530 | +1,22 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| FRESENIUS | 44,630 | +0,29 % | EQS-News: Fresenius SE & Co. KGaA: FutureFresenius zahlt sich aus: S&P Global Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Rating
FutureFresenius zahlt sich aus: S&P Global Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an
08.04.2026... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 37,740 | +1,07 % | GOLDMAN SACHS stuft Siemens Healthineers auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Siemens Healthineers von 52 auf 45 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Vor der Berichtssaison... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 45,940 | 0,00 % | BrightSpring Health Services, Inc. to Announce First Quarter 2026 Financial Results on May 1, 2026 | ||
| MIMEDX | 4,030 | 0,00 % | MiMedx Group, Inc: MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX Thyroid Shields | MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 22,720 | 0,00 % | What Makes Privia Health (PRVA) One of the Best Mid-Cap Growth Stocks to Invest in | ||
| HEARTFLOW | 27,070 | 0,00 % | Stifel reiterates Heartflow stock rating on clinical data strength | ||
| PROCEPT BIOROBOTICS | 23,260 | 0,00 % | PROCEPT BioRobotics to Report First Quarter 2026 Financial Results on April 29, 2026 | ||
| GERRESHEIMER | 17,170 | +1,00 % | Shortseller-Positionen aktuell: u.a. pbb, Gerresheimer, Hugo Boss, LANXESS, Puma, Sartorius, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BILLIONTOONE | 82,49 | -10,32 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| GENEDX | 59,97 | 0,00 % | Cathie Wood's ARK sells BWX Technologies stock, buys GeneDx | ||
| ECKERT & ZIEGLER | 14,630 | +1,81 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler sichert Zugang zu entscheidender Augentumorbehandlung durch MDR-Zertifizierung für Ru-106 Augenapplikatoren | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Zulassungsgenehmigung
Eckert & Ziegler sichert Zugang zu entscheidender Augentumorbehandlung durch MDR-Zertifizierung für Ru-106... ► Artikel lesen | |
| BETA BIONICS | 9,630 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 | IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 25,800 | +1,10 % | GOLDMAN SACHS stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Carl Zeiss Meditec von 36 auf 31 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Die Aktien der Jenaer... ► Artikel lesen |
FLUOGUIDE A/S gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 3,230 Euro und damit +3,86 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.